Paclitaxel loaded poly-d,l-lactide-co-glycolide nanoparticles: Enhanced anticancer effect in non-small cell lung carcinoma cell line

Biomedicine and Preventive Nutrition

Volumn 3, Issue 1, 2013, Pages 1-9

  Jose Merlin, J P ^a   Venkadesh, B ^a   Hussain, R ^a   Rajendra Prasad, N ^b   Shibli, S M A ^c   Raj, Anupama V ^c   Rajan, Sheeja S ^d  

^a Muslim arts college ^*  (India)

^b ANNAMALAI UNIVERSITY   (India)

^c UNIVERSITY OF KERALA   (India)

^d MANONMANIAM SUNDARANAR UNIVERSITY   (India)

Author keywords

Anticancer; Nanoparticles; Paclitaxel (PTX); Poly d,l lactide co glycolide (PLGA)

Indexed keywords

GLUTATHIONE; MATRIX METALLOPROTEINASE; PACLITAXEL; POLYGLACTIN; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; LUNG NON SMALL CELL CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOTHERAPY; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 84875268293     PISSN: 22105239     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bionut.2012.10.016     Document Type: Article

References (48)

1. Jemal A., Thun M.J., Ries L.A., Howe H.L., Weir H.K., Center M.M., et al. Annual report to the nation on the status of cancerm 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694.
2. Brown J.S., Eraut D., Trask C., et al. Age and the treatment of lung cancer. Thorax 1996, 51:564-568.
3. Tseng C.L., Su W.Y., Yen K.C., Yang K.C., Lin F.H. The use of biotinylated-EGF- modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009, 30:3476-3485.
4. D'Angelillo R.M., Trodella L., Ciresa M., Cellini F., Fiore M., Greco C., et al. Multimodality treatment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy. J Thorac Oncol 2009, 4:1517-1523.
5. Yoon C.J., Chung J.W., Park J.H., Yoon Y.H., Lee J.W., Jeong S.Y., et al. Transcatheter arterial chemoembolization with paclitaxellipiodol solution in rabbit VX2 liver tumor. Radiology 2003, 229:126-131.
6. Ishitobi M., Shin E., Kikkawa N. Metastatic breast cancer with resistance to both anthracycline and docetaxel successfully treated with weakly paclitaxel. Int J Clin Oncol 2001, 6(1):55-58.
7. Thigpen J.T. Chemotherapy for advanced ovarian cancer overview of randomized trials. Semin Oncol 2000, 27:11-16. (3 Suppl. 7).
8. Chang A.Y., Rubins J., Asbury R., Boros L., Hui L.F. Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol 2001, 28:10-13. (4 Suppl. 14).
9. Spencer C.M., Faulds D. Paclitaxel - a review of its pharmamcodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994, 48(5):794-847.
10. Schiff P., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by Taxol. Nature 1979, 277:665-667.
11. Panchagnula R. Pharmaceutical aspects of paclitaxel. Int J Pharm 1998, 172(1-2):1-15.
12. Danhier F., Lecouturier N., Vroman B., Jerome C., Marchand-Brynaert J., Feron O., et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 2009, 133:11-17.
13. Aghaei Moghaddam F., Atyabi F., Dinarvand R. Preparation and in vitro evaluation of mucoadhesion and permeation enhancement of thiolated chitosan-pHEMA core-shell nanoparticles. Nanomed Nanotechnol Biol Med 2009, 5:208-215.
14. Koziaraa J.M., Lockmanb P.R., Allenb D.D., Mumper R.J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release 2004, 99:259-269.
15. Caddeo C., Teska K., Sinico C., Kristl J. Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharmcol 2008, 363:183-191.
16. Leroux J.C., Doelker E., Gurny R. The use o obtained f drug-loaded nanoparticles in cancer chemotherapy. Microencapsulation 1996, 535-575. Marcel Dekker, New York. S. Benita (Ed.).
17. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer hemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
18. Hashida M., Akamatsu K., Nishikawa M., Yamashita F., Takakura Y. Design of polymeric prodrugs of prostaglandin E1 having galactose residue for hepatocyte targeting. J Control Release 1999, 62:253-262.
19. Nori A., Kopecek J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv Drug Deliv Rev 2005, 57:609-636.
20. Peterson C.M., Shiah J.G., Sun Y., Kopeckova P., Minko T., Straight R.C., et al. HPMA copolymer delivery of chemotherapy and photodynamic therapy in ovarian cancer. Adv Exp Med Biol 2003, 519:101-123.
21. Torchilin V.P., Lukyanov A.N. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 2003, 8:259-266.
22. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004, 22:969-976.
23. Cho K., Wang X., Nie S., Chen Z.G., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
24. Gomez-Gaete C. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharmacol 2007, 331:153-159.
25. Katare Y.K., Muthukumaran T., Panda A.K. Infl{ligature}uence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm 2005, 301:149-160.
26. Mathew M.E., Mohan J.C., Manzoor K., Nair S.V., Tamura H., Jayakumar R. Folate conjugated carboxymethyl chitosan-manganese doped zinc sulphide Nanoparticles for targeted drug delivery and imaging of cancer cells. Carbohyd Polym 2010, 80:443-449.
27. Dong Y., Feng S.S. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 2843-2849.
28. Mosmann T. Rapid calorimetric assay for cellular growth and survival: application of proliferation and cytotoxicity assay. J Immunol Methods 1983, 65(1-2):55-63.
29. Bhosle S.M., Huilgol N.G., Mishra K.P. Enhancement of radiation-induced oxidative stress and cytotoxicity in tumor cells by ellagic acid. Clin Chim Acta 2005, 359:89-100.
30. Rajendra Prasad N., Karthikeyan A., Karthikeyan S., Bandugula V.R. Inhibitory effect of caffeic acid on cancer cell proliferation by oxidative mechanism in human HT-1080 fibrosarcoma cell line. Mol Cell Biochem 2011, 349:11-19.
31. Lakshmi S., Dhanaya G.S., Joy B., Padmaja G., Remani P. Inhibitory effect of an extract of Curcuma Zedoariae on human cervical carcinoma cells. Med Chem Res 2008, 17:335-344.
32. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantification of low levels of DNA damage in individual cells. Exp Cell Res 1988, 175:184-191.
33. Nagarajan Rajendra Prasad, Kasinathan Jayanthimala, Samivel Ramachandran. Caffeic acid modulates ultraviolet radiation-B induced oxidative damage in human blood lymphocytes. J Photoch Photobio 2009, 95:196-203.
34. Niehaus W.G., Samuelsson B. Formation of malondialdehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem 1968, 6:126-130.
35. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
36. Cristina F., Sergio S., Rogerio G. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002, 83:273-286.
37. Vauthier-Holtzsherer C., Benabbou S., Spenlehauer G., Veillard M., Couvreur P. Methodology for the preparation of ultra-dispersed polymer systems. STP Pharma Sci 1991, 1(2):109-116.
38. Sanchez A., Vila-Jato J.L., Alonso M.J. Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporin A. Int J Pharm 1993, 99(2-3):263-273.
39. Chacon M., Berges L., Molpeceres J., Aberturas M.R., Guzman M. Optimized preparation of poly(D,L lactic-co-gly-colic) acid microspheres and nanospheres for oral administration. Int J Pharm 1996, 141(1-2):81-91.
40. Maaben S., Fattal E., Muller R.H., Couvreur P. Cell cultures for the assessment of toxicity and uptake of polymeric particulate drug carriers. STP Pharma Sci 1993, 3(1):11-22.
41. Bodmeier R., Maincent P. Polymeric dispersions as drug carriers. Pharmaceutical Dosage Forms: Disperse Systems 1998, 3:87-127. Marcel Dekker, New York.
42. Govender T., Stolnik S., Garnett M.C., Illum L., Davis S.S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 1999, 57(2):171-185.
43. Harris T.J., Green J.J., Fung P.W., Langer R., Anderson D.G., Bhatia S.N. Tissue-specifi{ligature}c gene delivery via nanoparticle coating. Biomaterials 2010, 31:998-1006.
44. Pauillard V., Nicolaou A., Double J.A., Philips R.M. Methionine dependence of tumours: a biochemical strategy for optimizing paclitaxel chemosensitivity in vitro. Biochem Pharmacol 2006, 71:772-778.
45. Halliwell B., Gutteridge J.M.C. Free radicals in biology and medicine 1989, Clarendon Press, Oxford.
46. Hildeman D.A., Mitchell T., Teague T.K., Henson P., Day B.J., Kappler J., et al. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity 1999, 10:735-744.
47. Zhang M., Boyer M., Rivory L., Hong A., Clarke S., Stevens G., et al. Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 2004, 58(2):353-360.
48. Mcmillan T.J., Steel G.G. DNA damage and cell killing 1997, 58-69. Basic Clin Radiol, London. G.G. Steel (Ed.).